Skip to main content

Advertisement

Table 2 Fold change (median) of genes after 4 weeks intervention with a mixture of c9t11 and t10c12 CLA, c9t11 CLA, and t10c12 CLA compared to control (LA) according to realtime PCR verification.

From: Isomer-specific effects of CLA on gene expression in human adipose tissue depending on PPARγ2 P12A polymorphism: a double blind, randomized, controlled cross-over study

  MIX C9T11 CLA T10c12 CLA  
Gene symbol [NCBI RefSeq] all Pro Ala all Pro Ala all Pro Ala  
Fatty acid transport and metabolism           PPARγ dependency
   ABCA9 [NM_080283.3] -1.3* -1.3*      -1.4*    n/a
   LDLR [NM_000527.3] 1.2** 1.8**      1.5** 1.5**   ↑[85]
   CD36 [NM_001001547.1]     -1.2*   -1.6* -1.3*   -1.2* ↑[65, 86]
   LIPE [NM_005357.2]    1.96†       1.8† ↑[23]
   CA3 [NM_005181.2]        -2.0** -2.0*   n/a
   FASN [NM_004104.4]   1.5*      1.2* 1.4*   ↑[87]
   SCD [NM_005063.4]    1.3*     1.5*   1.9* ↑[34, 88]
   FADS1 [NM_013402.3] 1.6* 1.6*         n/a
Transkription factors           
   PPARG [NM_138711.3]   -1.4**a 1.3 b        
   NFAT5 [NM_138713.2] -1.5* -1.6*      -1.6*   -1.9† n/a
   CREB5 [NM_182899.3]        -1.5*   -1.9† n/a
   EBF1 [NM_024007.3]   -1.5†         ↑[89]
Adipokines           
   ADIPOQ [NM_004797.29]    1.6†       1.5† ↑[90, 91]
   LEP [NM_000230.2]   -1.2 a 1.7†b        ↓[92]
   NAMPT [NM_005746.2]          -1.6* = [62]
   THBS1 [NM_003246.2]     1.5** 1.3* 1.5*     ↓[64] ↑[65]
Insulin signaling           
   IGF1 [NM_001111284.1]   -1.5†      -1.2** -1.2*   ↓ [93]
   SLC2A4 [NM_001042.2] 1.3*   1.5†        ↑[94]
   SORBS1 [NM_001034954.1]   -1.2*         ↑[74]
   PIK3R1 [NM_181523.1]   -1.6†         ↑[95]
Others           
   HPGD [NM_000860.3] -1.3**   -1.4**       -1.6* See text
   API5 [NM_006595.2]        -1.3†   -1.5* n/a
   CD74 [NM_001025158.1]   1.2*         n/a
   UCP2 [NM_003355.2] 1.14*         1.8† ↑[79]
   IL6ST [NM_175767.1] -1.3*       -1.5†   -1.8† n/a
  1. Comparison of CLA interventions and control (Wilcoxon test): *p < 0.05; **p < 0.001; † marks values with a tendency p ≤ 0.1 and more than +/- 1.5 fold change. Letters a and b indicate significant differences (p < 0.05) between effects in PPARγ2Pro12Pro (Pro; n = 23) and PPARγ2Ala12Ala (Ala; n = 11) carriers after the CLA mixture supplementation (Mann-Whitney U test).